Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1411

1.

Modified vaccinia Ankara: potential as an alternative smallpox vaccine.

McCurdy LH, Larkin BD, Martin JE, Graham BS.

Clin Infect Dis. 2004 Jun 15;38(12):1749-53. Epub 2004 May 19.

PMID:
15227622
[PubMed - indexed for MEDLINE]
Free Article
2.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

PMID:
15993917
[PubMed - indexed for MEDLINE]
Free Article
3.

Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.

Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO.

Vaccine. 2007 Jan 2;25(1):34-42. Epub 2006 Aug 1.

PMID:
16950548
[PubMed - indexed for MEDLINE]
4.

Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.

Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schätzl H, Busch DH, Sutter G, Goebel FD, Erfle V.

AIDS Res Hum Retroviruses. 2007 Jun;23(6):782-93.

PMID:
17604541
[PubMed - indexed for MEDLINE]
5.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.

J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.

PMID:
19012492
[PubMed - indexed for MEDLINE]
Free Article
6.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Gilbert SC.

Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Review.

PMID:
23523410
[PubMed - indexed for MEDLINE]
7.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team.

Vaccine. 2007 Feb 9;25(8):1513-25. Epub 2006 Nov 7.

PMID:
17126963
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Jones T.

Curr Opin Mol Ther. 2008 Aug;10(4):407-17.

PMID:
18683106
[PubMed - indexed for MEDLINE]
9.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.

PMID:
18678911
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants.

Hartnack S, Essbauer S, Truyen U.

Zoonoses Public Health. 2008;55(2):99-105. doi: 10.1111/j.1863-2378.2007.01094.x.

PMID:
18234028
[PubMed - indexed for MEDLINE]
11.

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.

Coulibaly S, Brühl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG.

Virology. 2005 Oct 10;341(1):91-101.

PMID:
16061267
[PubMed - indexed for MEDLINE]
Free Article
12.

Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P.

J Infect Dis. 2013 Mar 1;207(5):749-58. doi: 10.1093/infdis/jis753. Epub 2012 Dec 7.

PMID:
23225902
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

New generation smallpox vaccines: a review of preclinical and clinical data.

Artenstein AW.

Rev Med Virol. 2008 Jul-Aug;18(4):217-31. doi: 10.1002/rmv.571. Review.

PMID:
18283712
[PubMed - indexed for MEDLINE]
14.

Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.

Kremer M, Suezer Y, Volz A, Frenz T, Majzoub M, Hanschmann KM, Lehmann MH, Kalinke U, Sutter G.

PLoS Pathog. 2012;8(3):e1002557. doi: 10.1371/journal.ppat.1002557. Epub 2012 Mar 1.

PMID:
22396645
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.

Volz A, Sutter G.

Vaccine. 2013 Sep 6;31(39):4235-40. doi: 10.1016/j.vaccine.2013.03.016. Epub 2013 Mar 21. Review.

PMID:
23523402
[PubMed - indexed for MEDLINE]
16.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

PMID:
18199639
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Smallpox vaccines: Past, present, and future.

Parrino J, Graham BS.

J Allergy Clin Immunol. 2006 Dec;118(6):1320-6. Review.

PMID:
17157663
[PubMed - indexed for MEDLINE]
18.

[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schäfer H, Holzner A.

Dtsch Med Wochenschr. 1974 Nov 22;99(47):2386-92. German. No abstract available.

PMID:
4426258
[PubMed - indexed for MEDLINE]
19.

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Sutter G, Staib C.

Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. Review.

PMID:
14529359
[PubMed - indexed for MEDLINE]
20.

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P.

Vaccine. 2006 Mar 15;24(12):2065-70. Epub 2005 Nov 28.

PMID:
16337719
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk